DMRA: Damora Therapeutics, Inc. (NASDAQ: DMRA)
One-sentence key finding: Damora Therapeutics is a small clinical-stage biotechnology company (formerly Galecto) that pivoted via a 2025 acquisition and name change to focus on mutant CALR-driven blood disorders, with its stock showing extreme volatility and massive 1-year gains amid analyst optimism but ongoing clinical and financial risks.
Company Overview (Facts)
- Business: Develops novel biologics targeting mutant calreticulin (mutCALR) for myeloproliferative neoplasms (MPNs) such as essential thrombocythemia (ET) and myelofibrosis (MF), plus GB3226 (small molecule) for acute myeloid leukemia (AML).
- Lead Assets: DMR-001 (Fc-null anti-mutCALR monoclonal antibody for ET); DMR-002/DMR-003 (broader mutCALR coverage); preclinical data planned for EHA 2026 congress.
- Headquarters: Waltham, Massachusetts.
- Employees: 7 (small team).
- Website: damoratx.com (IR: galecto.gcs-web.com).
- CEO: Jennifer A. Jarrett (appointed March 2026).
Fact: Clinical-stage with no approved products or revenue; focused on disease-modifying therapies for unmet needs in hematologic disorders.
Company History (Facts)
- Founded in 2011 as Galecto, Inc., initially developing small-molecule inhibitors of galectin-3 and LOXL2 for fibrosis and cancer.
- November 2025: Acquired privately held Damora Therapeutics (focused on mutCALR assets from Paragon/Fairmount) + concurrent ~$285 million PIPE financing.
- March 2026: Name change to Damora Therapeutics, Inc.; ticker changed from GLTO to DMRA (effective March 10, 2026).
- March 2026: Appointed Jennifer Jarrett as President & CEO; added two industry veterans to the board.
Interpretation: The rebrand and pivot represent a strategic reset toward higher-potential hematology assets, supported by significant new capital.
Recent News & Developments (as of early July 2026)
- July 1, 2026: Inducement equity grants under Nasdaq Rule 5635(c)(4) for new non-executive hires.
- June 2026: Multiple inducement grants; added to Russell 2000/2500/3000 indexes (late June).
- May 12, 2026: Q1 2026 earnings and corporate highlights (preclinical data updates; on track for regulatory submissions).
- March–June 2026: Series of analyst initiations/upgrades (e.g., Buy/Outperform from RBC Capital, Wedbush, H.C. Wainwright, TD Cowen, Guggenheim).
- Full-year 2025 earnings reported March 19, 2026.
Fact: Heavy emphasis on hiring, financing milestones, and pipeline advancement; predominantly positive analyst coverage.
Stock Performance (Facts & Data as of ~July 2026)
| Metric | Value |
|---|
| Recent Price Range (intraday examples) | $27.18 – $30.35 |
| 52-Week Range | $2.45 – $38.33 |
| Market Cap | ~$1.7B – $1.85B |
| YTD Return | ~27% (vs. S&P 500 ~10%) |
| 1-Year Return | ~757% (vs. S&P 500 ~20%) |
| Analyst Consensus | Strong Buy; Avg. Target ~$43.38 (High $51) |
| EPS (TTM) | -$2.68 |
| Cash Position (recent) | ~$533M |
Uncertainty/Limitation: Prices and returns are snapshots and highly volatile (typical for clinical-stage biotechs); no dividends; P/E not meaningful due to losses. Data sourced from Yahoo Finance, Robinhood, MarketWatch, etc. (verify live).
- Key Links for More Information:
Key Risks & Assumptions (Flagged)
- High Uncertainty: Clinical-stage biotech — success depends on trial results, regulatory approvals (first submissions targeted 2026+), and competition. Cash burn is significant (net loss ~$235M TTM).
- Interpretation: Massive stock gains reflect optimism around the pivot and pipeline but could reverse on any setbacks.
- Limitations: Information current as of early July 2026 (date: July 10, 2026); financials and pipeline status subject to updates in SEC filings/earnings. Small employee count and pre-revenue status indicate execution risk. Always cross-verify with latest 10-Q/8-K and consult professionals.